In the pediatric population, the goal is to try to aim for an LDL of less than 130. So lipid apheresis is FDA-approved in both adults and children for the treatment of HoFH.

Low-density lipoprotein (LDL) cholesterol apheresis is an effective treatment in lowering LDL cholesterol, improving clinical endpoints, and lowering lipoprotein(a) [Lp(a)] in patients with ...

There's a treatment called LDL apheresis that's designed for people who can't lower their abnormally high levels of "lousy" LDL cholesterol with lifestyle changes and medications. LDL apheresis ...

Semiweekly LDL-apheresis added to treatment with lipid-lowering drugs led to marked regression of coronary plaque compared with treatment with drugs alone in this small study of patients with ...

LAS VEGAS — LDL apheresis was safe and was linked to a trend toward early coronary atheroma regression in patients with ACS and high LDL who underwent PCI, according to data from the PREMIER ...

Sept. 4, 2003 — Editor's Note: Low-density lipoprotein (LDL) apheresis may benefit patients with persistent, symptomatic LDL cholesterol elevations or genetic LDL abnormalities refractory to ...

Familial hypercholesterolemia is an autosomal dominant disorder resulting in severe elevation of total and LDL cholesterol due to defective hepatic LDL receptor. Heterozygotes occur in about 1 of ...

Overall, LDL apheresis lowered LDL by 56% in the study arm, substantially greater than the 17% reduction observed in the statin only cohort. In both the intention-to-treat and as-observed analyses, ...

May 23 (UPI) --A new treatment might be able to remove "bad cholesterol" from the blood in a matter of hours, a recent study says.Within two to three hours, a procedure known as LDL apheresis ...

LDL apheresis is done under the guidance of medical specialists from Loyola's transfusion service, and patients have periodic clinical follow-ups with a lipidologist (cholesterol specialist).

Low-density lipoprotein (LDL) cholesterol apheresis is an effective treatment in lowering LDL cholesterol, improving clinical endpoints, and lowering lipop ...